Director: Dr Giorgia Querin
I-Motion Pediatric was created at the behest of four partners, the Institute of Myology, AFM-Téléthon, the AP-HP (Paris public hospital system), and Sorbonne University, and is a paediatric clinical trial platform for neuromuscular diseases. Its objective is to meet the new needs created by the emergence of therapies for diseases that were long-considered incurable, many of which affect children.
Located at the site of the Trousseau Paediatric Hospital in the Division of Infant surgery headed by Prof. Raphaël Vialle, part of the AP-HP (the Paris public hospital system), in the Lemariey building, I-Motion is designed to treat young patients under the best conditions possible, in a tailored, welcoming and secure environment. It benefits from accessibility to the technical platforms, research structures and clinical services of Trousseau Hospital. All of the consultations and specialists can be found at a single location, which also facilitates the follow-up and treatment process, for the children and also for their parents.
As well as its medical care and clinical trial activities, I-Motion Pediatric develops measurement tools to assess the efficacy of treatments, and is also responsible for collecting and storing biological samples.
Access the complete list of registries, databases and clinical trials currently running at the Institute.
Team members
Dr Giorgia Querin, MD, PhD, neurologist, Director
Khadija Boukouti, Executive Assistant
Dr Marina Colella, MD, PhD, Paediatrician
Dr Andreea Seferian, Paediatric Neurologist
Dr Silvana De Lucia, Paediatric Neurologist
Marta Gomez Garcia de La Banda, MD, Paediatric Neurologist
Malgorzata Tota, Medical Secretary
Dominique Duchêne, Project Manager, Clinical Research Associates (CRA) Coordinator
Férial Toumi, PhD, Project Manager, Clinical Research Associate (CRA)
Erwan Gasnier, PhD, Project Manager
Maya Ould-Said, Quality Engineer
Smaïl Ait Mohand, Clinical Research Associate (CRA)
Marta Peretti, PhD, Clinical Research Associate (CRA)
Aurélie Phelep, PhD, Clinical Research Associate (CRA)
Nawal Halfaoui, Clinical Research Associate (CRA)
Ouamer Nait-Slimani, Clinical Research Associate (CRA)
Rima Belhamdi, Clinical Research Associate (CRA)
Allison Grangé, Physiotherapist
Darko Milascevic, Physiotherapist
Key publications
- Gidaro T, Reyngoudt H, Le Louër J, Behin A, Toumi F, Villeret M, Araujo ECA, Baudin PY, Marty B, Annoussamy M, Hogrel JY, Carlier PG, Servais L. Quantitative nuclear magnetic resonance imaging detects subclinical changes over 1 year in skeletal muscle of GNE myopathy. J Neurol. 2019 Oct 15. doi: 10.1007/s00415-019-09569-6. [Epub ahead of print]
- Gidaro T, Reyngoudt H, Le Louër J, Behin A, Toumi F, Villeret M, Araujo ECA, Baudin PY, Marty B, Annoussamy M, Hogrel JY, Carlier PG, Servais L. Quantitative nuclear magnetic resonance imaging detects subclinical changes over 1 year in skeletal muscle of GNE myopathy. J Neurol. 2019 Oct 15. doi: 10.1007/s00415-019-09569-6. [Epub ahead of print]
- Annoussamy M, Lilien C, Gidaro T, Gargaun E, Chê V, Schara U, Gangfuß A, D’Amico A, Dowling JJ, Darras BT, Daron A, Hernandez A, de Lattre C, Arnal JM, Mayer M, Cuisset JM, Vuillerot C, Fontaine S, Bellance R, Biancalana V, Buj-Bello A, Hogrel JY, Landy H, Servais L. X-linked myotubular myopathy: A prospective international natural history study. Neurology. 2019 Apr 16;92(16):e1852-e1867. doi: 10.1212/WNL.0000000000007319. Epub 2019 Mar 22.
- Vandersmissen I, Biancalana V, Servais L, Dowling JJ, Vander Stichele G, Van Rooijen S, Thielemans L. An integrated modelling methodology for estimating the prevalence of centronuclear myopathy. Neuromuscul Disord. 2018 Sep;28(9):766-777. doi: 10.1016/j.nmd.2018.06.012. Epub 2018 Jul 1. Review.
- Chabanon A, Seferian AM, Daron A, Péréon Y, Cances C, Vuillerot C, De Waele L, Cuisset JM, Laugel V, Schara U, Gidaro T, Gilabert S, Hogrel JY, Baudin PY, Carlier P, Fournier E, Lowes LP, Hellbach N, Seabrook T, Toledano E, Annoussamy M, Servais L; NatHis-SMA study group. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS One. 2018 Jul 26;13(7):e0201004. doi: 10.1371/journal.pone.0201004. eCollection 2018.
- Aragon-Gawinska K, Seferian AM, Daron A, Gargaun E, Vuillerot C, Cances C, Ropars J, Chouchane M, Cuppen I, Hughes I, Illingworth M, Marini-Bettolo C, Rambaud J, Taytard J, Annoussamy M, Scoto M, Gidaro T, Servais L. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study. Neurology. 2018 Oct 2;91(14):e1312-e1318. doi: 10.1212/WNL.0000000000006281. Epub 2018 Aug 29.
- Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol. 2019 Jan;61(1):19-24. doi: 10.1111/dmcn.14027. Epub 2018 Sep 17. Review.
- Lilien C, Gasnier E, Gidaro T, Seferian A, Grelet M, Vissière D, Servais L. Home-Based Monitor for Gait and Activity Analysis. J Vis Exp. 2019 Aug 8;(150). doi: 10.3791/59668.
- Anghelescu C, Francou B, Cardas R, Guiochon-Mantel A, Aubourg P, Servais L, Gidaro T. Targeted exomes reveal simultaneous MFN2 and GDAP1 mutations in a severe Charcot-Marie-Tooth disease type 2 phenotype. Eur J Neurol. 2017 Mar;24(3):e15-e16. doi: 10.1111/ene.13250. No abstract available.
- Cardas R, Iliescu C, Butoianu N, Seferian A, Gataullina S, Gargaun E, Nectoux J, Bienvenu T, Craiu D, Gidaro T, Servais L. DMD and West syndrome. Neuromuscul Disord. 2017 Oct;27(10):911-913. doi: 10.1016/j.nmd.2017.07.008. Epub 2017 Jul 19.
- Seferian AM, Malfatti E, Bosson C, Pelletier L, Taytard J, Forin V, Gidaro T, Gargaun E, Carlier P, Fauré J, Romero NB, Rendu J, Servais L. Mild clinical presentation in KLHL40-related nemaline myopathy (NEM 8). Neuromuscul Disord. 2016 Oct;26(10):712-716. doi: 10.1016/j.nmd.2016.07.011. Epub 2016 Jul 29.
- Hogrel JY, Wary C, Moraux A, Azzabou N, Decostre V, Ollivier G, Canal A, Lilien C, Ledoux I, Annoussamy M, Reguiba N, Gidaro T, Le Moing AG, Cardas R, Voit T, Carlier PG, Servais L. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. Neurology. 2016 Mar 15;86(11):1022-30. doi: 10.1212/WNL.0000000000002464. Epub 2016 Feb 17.
- Servais L, Montus M, Guiner CL, Ben Yaou R, Annoussamy M, Moraux A, Hogrel JY, Seferian AM, Zehrouni K, Le Moing AG, Gidaro T, Vanhulle C, Laugel V, Butoianu N, Cuisset JM, Sabouraud P, Cances C, Klein A, Leturcq F, Moullier P, Voit T. Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype. J Neuromuscul Dis. 2015 Sep 2;2(3):269-279.
- Servais L, Deconinck N, Moraux A, Benali M, Canal A, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Desguerre I, Maincent K, Themar-Noel C, Quijano-Roy S, Serari N, Voit T, Hogrel JY. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord. 2013 Feb;23(2):139-48. doi: 10.1016/j.nmd.2012.10.022. Epub 2012 Dec 5.